

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Dabrafenib in combination with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer (review of technology appraisal 564) [ID3851]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

n/a

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

Health Technology Evaluation: Scoping
Equality impact assessment for the Health Technology Evaluation of Dabrafenib in combination with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer

No

Approved by Associate Director (name): ...Linda Landells

Date: 26 May 2022